Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wheatgrass juice (WGJ) is a nutritional supplement extracted from the young sprouts of the common wheat plant, *Triticum aestivum*. It is characterized by high concentrations of chlorophyll, amino acids, minerals, vitamins, and enzymes. In clinical research conducted at the Rambam Health Care Campus (notably trial NCT01991080), WGJ has been investigated as a supportive therapy for patients with stage II-III colorectal cancer receiving adjuvant chemotherapy (such as capecitabine or 5-fluorouracil with oxaliplatin). The juice is hypothesized to exert anti-inflammatory and immunomodulatory effects by influencing cytokine profiles (e.g., IL-6, IL-8, IL-10, and IL-12) and may help reduce chemotherapy-induced myelotoxicity, potentially improving patient quality of life and treatment adherence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wheatgrass juice.